CN Patent

CN112661751B — 作为bcl-2抑制剂的杂环化合物

Assigned to Nanjing Innocare Pharma Tech Co ltd · Expires 2024-06-14 · 2y expired

What this patent protects

本发明涉及化合物、含有其的药物组合物、以及它们的制备方法,和其作为B细胞淋巴瘤‑2（BCL‑2）抑制剂的用途。所述化合物为式I所示的化合物，或其异构体、前药、溶剂合物、稳定的同位素衍生物或其药学上可接受的盐。本发明还涉及所述化合物或含有其的组合物用于治疗或预防由BCL‑2介导的相关疾病例如肿瘤的用途。

USPTO Abstract

本发明涉及化合物、含有其的药物组合物、以及它们的制备方法,和其作为B细胞淋巴瘤‑2（BCL‑2）抑制剂的用途。所述化合物为式I所示的化合物，或其异构体、前药、溶剂合物、稳定的同位素衍生物或其药学上可接受的盐。本发明还涉及所述化合物或含有其的组合物用于治疗或预防由BCL‑2介导的相关疾病例如肿瘤的用途。

Drugs covered by this patent

Patent Metadata

Patent number
CN112661751B
Jurisdiction
CN
Classification
—
Expires
2024-06-14
Drug substance claim
No
Drug product claim
No
Assignee
Nanjing Innocare Pharma Tech Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.